Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (249)	3/22/2002 12:41:45 PM
From: seminole	Read Replies (1) \| Respond to of 544

Don't see any buying after ABT dump. Good luck playing SUPG bounce. Their phase III pancreatic data has not been summitted. It is late. <<< SUPG has rebranded Rubitecan >>> This can be taken as a warning that the pancreatic trial data is not great. <<< ABT terminated their alliance >>> This can be taken as a warning that the pancreatic trial data is not great.

To: Jibacoa who wrote (249)	3/22/2002 12:47:54 PM
From: Jibacoa	Respond to of 544

VPHM Is trying to come back today after the C.C. yesterday evening.<g> Regarding Picovir, they stated that "This drug is not dead," and "We continue to have confidence in the data and in the drug," and that they plan to meet with FDA officials in near future. The volume is now above 1.3M (about 2x its daily average)and the stock is up 8.6% (not bad for one day.<g>)But still it is far from been able to close its Mar.20 down-gap. siliconinvestor.com siliconinvestor.com Bernard